| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
4,396 |
3,193 |
$330K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,726 |
1,509 |
$139K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
1,891 |
1,470 |
$84K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
1,272 |
1,057 |
$57K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
1,262 |
978 |
$54K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
744 |
564 |
$51K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,364 |
1,235 |
$32K |
| 96160 |
|
2,141 |
1,541 |
$31K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
204 |
194 |
$29K |
| 96127 |
|
1,356 |
1,140 |
$19K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
233 |
154 |
$17K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
466 |
430 |
$16K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
302 |
220 |
$15K |
| 87503 |
|
689 |
528 |
$12K |
| 0240U |
|
69 |
66 |
$10K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
743 |
604 |
$9K |
| 94760 |
|
1,990 |
1,640 |
$8K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
208 |
191 |
$6K |
| 87634 |
|
105 |
81 |
$5K |
| 86328 |
|
121 |
80 |
$5K |
| 99384 |
|
42 |
30 |
$4K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
161 |
110 |
$4K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
87 |
86 |
$3K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
167 |
157 |
$3K |
| 92551 |
|
122 |
98 |
$2K |
| 81002 |
|
618 |
498 |
$2K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
12 |
12 |
$1K |
| 99173 |
|
53 |
48 |
$394.85 |
| G2012 |
Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion |
28 |
20 |
$322.98 |
| 81001 |
|
110 |
99 |
$308.88 |
| 85018 |
|
46 |
31 |
$106.72 |
| 86580 |
|
17 |
17 |
$88.74 |